Search

Your search keyword '"Berthold, Dominik-R"' showing total 124 results
Start Over Author "Berthold, Dominik-R"
124 results on '"Berthold, Dominik-R"'

1. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial

Author

Papachristofilou, Alexandros, Bedke, Jens, Hayoz, Stefanie, Schratzenstaller, Ulrich, Pless, Miklos, Hentrich, Marcus, Krege, Susanne, Lorch, Anja, Aebersold, Daniel-M, Putora, Paul Martin, Berthold, Dominik-R, Zihler, Deborah, Zengerling, Friedemann, Dieing, Annette, Mueller, Arndt-Christian, Schaer, Corinne, Biaggi, Christine, Gillessen, Silke, and Cathomas, Richard

Published
2022
Full Text
View/download PDF

2. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers

Author

Martinez Chanza, Nieves, Werner, Lillian, Plimack, Elizabeth, Yu, Evan Y., Alva, Ajjai S., Crabb, Simon J., Powles, Thomas, Rosenberg, Jonathan E., Baniel, Jack, Vaishampayan, Ulka N., Berthold, Dominik R., Ladoire, Sylvain, Hussain, Syed A., Milowsky, Matthew I., Agarwal, Neeraj, Necchi, Andrea, Pal, Sumanta K., Sternberg, Cora N., Bellmunt, Joaquim, Galsky, Matthew D., and Harshman, Lauren C.

Published
2020
Full Text
View/download PDF

3. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study

Author

Necchi, Andrea, Pond, Gregory R., Smaldone, Marc C., Pal, Sumanta K., Chan, Kevin, Wong, Yu-Ning, Viterbo, Rosalia, Sonpavde, Guru, Harshman, Lauren C., Crabb, Simon, Alva, Ajjai, Chowdhury, Simon, De Giorgi, Ugo, Srinivas, Sandy, Agarwal, Neeraj, Bamias, Aristotelis, Baniel, Jack, Golshayan, Ali-Reza, Ladoire, Sylvain, Sternberg, Cora N., Cerbone, Linda, Yu, Evan Y., Bellmunt, Joaquim, Vaishampayan, Ulka, Niegisch, Gunter, Hussain, Syed, Bowles, Daniel W., Morales-Barrera, Rafael, Milowsky, Matthew I., Theodore, Christine, Berthold, Dominik R., Sridhar, Srikala S., Powles, Thomas, Rosenberg, Jonathan E., and Galsky, Matthew D.

Published
2018
Full Text
View/download PDF

4. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma

Author

Sonpavde, Guru P., Mariani, Luigi, Lo Vullo, Salvatore, Raggi, Daniele, Giannatempo, Patrizia, Bamias, Aristotle, Crabb, Simon J., Bellmunt, Joaquim, Yu, Evan Y., Niegisch, Guenter, Vaishampayan, Ulka N., Theodore, Christine, Berthold, Dominik R., Srinivas, Sandy, Sridhar, Srikala S., Plimack, Elizabeth R., Rosenberg, Jonathan E., Powles, Thomas, Galsky, Matthew D., and Necchi, Andrea

Published
2018
Full Text
View/download PDF

5. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population

Author

Necchi, Andrea, Pond, Gregory R., Pal, Sumanta K., Agarwal, Neeraj, Bowles, Daniel W., Plimack, Elizabeth R., Yu, Evan Y., Ladoire, Sylvain, Baniel, Jack, Crabb, Simon, Niegisch, Gunter, Srinivas, Sandy, Berthold, Dominik R., Rosenberg, Jonathan E., Powles, Thomas, Bamias, Aristotelis, Harshman, Lauren C., Bellmunt, Joaquim, and Galsky, Matthew D.

Published
2018
Full Text
View/download PDF

6. Supplementary Table from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Author

Herrera, Fernanda G., primary, Ronet, Catherine, primary, Ochoa de Olza, Maria, primary, Barras, David, primary, Crespo, Isaac, primary, Andreatta, Massimo, primary, Corria-Osorio, Jesus, primary, Spill, Aodrenn, primary, Benedetti, Fabrizio, primary, Genolet, Raphael, primary, Orcurto, Angela, primary, Imbimbo, Martina, primary, Ghisoni, Eleonora, primary, Navarro Rodrigo, Blanca, primary, Berthold, Dominik R., primary, Sarivalasis, Apostolos, primary, Zaman, Khalil, primary, Duran, Rafael, primary, Dromain, Clarisse, primary, Prior, John, primary, Schaefer, Niklaus, primary, Bourhis, Jean, primary, Dimopoulou, Georgia, primary, Tsourti, Zoi, primary, Messemaker, Marius, primary, Smith, Thomas, primary, Warren, Sarah E., primary, Foukas, Periklis, primary, Rusakiewicz, Sylvie, primary, Pittet, Mikaël J., primary, Zimmermann, Stefan, primary, Sempoux, Christine, primary, Dafni, Urania, primary, Harari, Alexandre, primary, Kandalaft, Lana E., primary, Carmona, Santiago J., primary, Dangaj Laniti, Denarda, primary, Irving, Melita, primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Author

Herrera, Fernanda G., primary, Ronet, Catherine, primary, Ochoa de Olza, Maria, primary, Barras, David, primary, Crespo, Isaac, primary, Andreatta, Massimo, primary, Corria-Osorio, Jesus, primary, Spill, Aodrenn, primary, Benedetti, Fabrizio, primary, Genolet, Raphael, primary, Orcurto, Angela, primary, Imbimbo, Martina, primary, Ghisoni, Eleonora, primary, Navarro Rodrigo, Blanca, primary, Berthold, Dominik R., primary, Sarivalasis, Apostolos, primary, Zaman, Khalil, primary, Duran, Rafael, primary, Dromain, Clarisse, primary, Prior, John, primary, Schaefer, Niklaus, primary, Bourhis, Jean, primary, Dimopoulou, Georgia, primary, Tsourti, Zoi, primary, Messemaker, Marius, primary, Smith, Thomas, primary, Warren, Sarah E., primary, Foukas, Periklis, primary, Rusakiewicz, Sylvie, primary, Pittet, Mikaël J., primary, Zimmermann, Stefan, primary, Sempoux, Christine, primary, Dafni, Urania, primary, Harari, Alexandre, primary, Kandalaft, Lana E., primary, Carmona, Santiago J., primary, Dangaj Laniti, Denarda, primary, Irving, Melita, primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Data from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Author

Herrera, Fernanda G., primary, Ronet, Catherine, primary, Ochoa de Olza, Maria, primary, Barras, David, primary, Crespo, Isaac, primary, Andreatta, Massimo, primary, Corria-Osorio, Jesus, primary, Spill, Aodrenn, primary, Benedetti, Fabrizio, primary, Genolet, Raphael, primary, Orcurto, Angela, primary, Imbimbo, Martina, primary, Ghisoni, Eleonora, primary, Navarro Rodrigo, Blanca, primary, Berthold, Dominik R., primary, Sarivalasis, Apostolos, primary, Zaman, Khalil, primary, Duran, Rafael, primary, Dromain, Clarisse, primary, Prior, John, primary, Schaefer, Niklaus, primary, Bourhis, Jean, primary, Dimopoulou, Georgia, primary, Tsourti, Zoi, primary, Messemaker, Marius, primary, Smith, Thomas, primary, Warren, Sarah E., primary, Foukas, Periklis, primary, Rusakiewicz, Sylvie, primary, Pittet, Mikaël J., primary, Zimmermann, Stefan, primary, Sempoux, Christine, primary, Dafni, Urania, primary, Harari, Alexandre, primary, Kandalaft, Lana E., primary, Carmona, Santiago J., primary, Dangaj Laniti, Denarda, primary, Irving, Melita, primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

9. Data from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Author

Herrera, Fernanda G., primary, Ronet, Catherine, primary, Ochoa de Olza, Maria, primary, Barras, David, primary, Crespo, Isaac, primary, Andreatta, Massimo, primary, Corria-Osorio, Jesus, primary, Spill, Aodrenn, primary, Benedetti, Fabrizio, primary, Genolet, Raphael, primary, Orcurto, Angela, primary, Imbimbo, Martina, primary, Ghisoni, Eleonora, primary, Navarro Rodrigo, Blanca, primary, Berthold, Dominik R., primary, Sarivalasis, Apostolos, primary, Zaman, Khalil, primary, Duran, Rafael, primary, Dromain, Clarisse, primary, Prior, John, primary, Schaefer, Niklaus, primary, Bourhis, Jean, primary, Dimopoulou, Georgia, primary, Tsourti, Zoi, primary, Messemaker, Marius, primary, Smith, Thomas, primary, Warren, Sarah E., primary, Foukas, Periklis, primary, Rusakiewicz, Sylvie, primary, Pittet, Mikaël J., primary, Zimmermann, Stefan, primary, Sempoux, Christine, primary, Dafni, Urania, primary, Harari, Alexandre, primary, Kandalaft, Lana E., primary, Carmona, Santiago J., primary, Dangaj Laniti, Denarda, primary, Irving, Melita, primary, and Coukos, George, primary

Published
2023
Full Text
View/download PDF

10. Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.

Author

Mourey, Loic, primary, Boyle, Helen Jane, additional, Roubaud, Guilhem, additional, McDermott, Raymond S., additional, Supiot, Stephane, additional, Tombal, Bertrand F., additional, Flechon, Aude, additional, Berthold, Dominik R., additional, Ronchin, Philippe, additional, Kacso, Gabriel, additional, Berdah, Jean Francois, additional, Calabro, Fabio, additional, Gravis, Gwenaelle, additional, Palumbo, Samuel, additional, Gil, Thierry, additional, Vie, Brigitte, additional, Ribault, Hélène, additional, Fizazi, Karim, additional, Foulon, Stéphanie, additional, and Carles, Joan, additional

Published
2023
Full Text
View/download PDF

11. Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.

Author

Cathomas, Richard, primary, Rothschild, Sacha, additional, Hayoz, Stefanie, additional, Spahn, Martin, additional, Özdemir, Berna, additional, Kiss, Bernhard, additional, Erdmann, Andreas, additional, Aeppli, Stefanie, additional, Mach, Nicolas, additional, Strebel, Raeto, additional, Hadaschik, Boris A., additional, Berthold, Dominik R., additional, Pless, Miklos, additional, Zihler, Deborah, additional, Schmid, Mathias, additional, Schneider, Martina, additional, Musilova, Jana, additional, and Petrausch, Ulf, additional

Published
2022
Full Text
View/download PDF

12. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Author

James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gerhardt, Brawley, Christopher D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., de Bono, Johann S., Diaz‐Montana, Carlos, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominik R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W. S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob S., Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K. B., Sydes, Matthew R., James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gerhardt, Brawley, Christopher D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., de Bono, Johann S., Diaz‐Montana, Carlos, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominik R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W. S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob S., Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K. B., and Sydes, Matthew R.

Abstract

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50-0.71; P = 0.31 × 10−9) favoured SOC + AAP, with 5-years survival improved from 41% SOC-alone to 60% SOC + AAP. This was similar in low-risk (HR = 0.55; 95% CI: 0.41-0.76) and high-risk (HR = 0.54; 95% CI: 0.43-0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.

Published
2022

14. Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.

Author

Roubaud, Guilhem, primary, Kostine, Marie, additional, McDermott, Raymond S., additional, Bernard-Tessier, Alice, additional, Maldonado, Xavier, additional, Silva, Marlon, additional, Flechon, Aude, additional, Berthold, Dominik R., additional, Ronchin, Philippe, additional, Tombal, Bertrand F., additional, Mourey, Loic, additional, Gravis, Gwenaelle, additional, Escande, Anne, additional, Abadie Lacourtoisie, Sophie, additional, Thiery-Vuillemin, Antoine, additional, Climent Duran, Miguel Angel A., additional, Ribault, Hélène, additional, Bossi, Alberto, additional, Foulon, Stéphanie, additional, and Fizazi, Karim, additional

Published
2022
Full Text
View/download PDF

16. List of Contributors

Author

Alix-Panabieres, Catherine, primary, Arlt, Matthias J.E., additional, Bataille, Regis, additional, Bedard, Gillian, additional, Berthold, Dominik R., additional, Bianco, Paolo, additional, Blanchard, Frédéric, additional, Blay, Jean-Yves, additional, Bolton, Damien, additional, Bolzoni, Marina, additional, Born, Walter, additional, Botter, Sander M., additional, Bouvier, Corinne, additional, Brounais-Le Royer, Bénédicte, additional, Brown, Nicola J., additional, Buijs, Jeroen T., additional, Camacho, Daniel F., additional, Campbell, Preston, additional, Chappard, Daniel, additional, Chartier, Stephane, additional, Chou, Hong, additional, Chow, Edward, additional, Chow, Ronald, additional, Christoulas, Dimitrios, additional, Cleton-Jansen, Anne-Marie, additional, Clézardin, Philippe, additional, Clohisy, Denis R., additional, Coleman, Robert, additional, Corradini, Nadège, additional, Croset, Martine, additional, de Pinieux, Gonzague, additional, Derbel, Olfa, additional, Desiderio, Vincenzo, additional, Edwards, James R., additional, Elefteriou, Florent, additional, Fealk, Michelle, additional, Flanagan, Adrienne M., additional, Fournier, Pierrick G.J., additional, Fromigué, Olivia, additional, Fuchs, Bruno, additional, Gao, Dingcheng, additional, Gikas, Panagiotis D., additional, Giuliani, Nicola, additional, Gnant, Michael, additional, Gomez-Brouchet, Anne, additional, Gosheger, Georg, additional, Gouin, François, additional, Guise, Theresa A., additional, Harada, Shuko, additional, Hardes, Jendrik, additional, Hauben, Esther I., additional, He, Wei, additional, Herrera, Fernanda G., additional, Heymann, Marie-Françoise, additional, Hicks, David G., additional, Hogendoorn, Pancras C.W., additional, Holen, Ingunn, additional, Ilaslan, Hakan, additional, Isidor, Bertrand, additional, Jacques, Camille, additional, Juàrez, Patricia, additional, Junankar, Simon, additional, Kabelitz, Dieter, additional, Kalyan, Shirin, additional, Kontny, Udo, additional, Knuutila, Sakari, additional, La Noce, Marcella, additional, Lamora, Audrey, additional, Lamoureux, Francois, additional, Lao, Nicholas, additional, Lawrentschuk, Nathan, additional, Lawson, Michelle A., additional, Lecanda, Fernando, additional, Lee, Jiyun, additional, Lézot, Frédéric, additional, Li, Shibo, additional, Lissat, Andrej, additional, Ludwig, Joseph, additional, Määttä, Jorma A., additional, Mallinson, Paul I., additional, Mantyh, Patrick W., additional, Marie, Pierre J., additional, Mavrogenis, Andreas F., additional, Mikkilineni, Himabindu, additional, Mittal, Vivek, additional, Modrowski, Dominique, additional, Munk, Peter L., additional, Navet, Benjamin, additional, Niini, Tarja, additional, O’Donnell, Patrick W., additional, Odri, Guillaume, additional, Ory, Benjamin, additional, Ouellette, Hugue A., additional, Paino, Francesca, additional, Pantel, K., additional, Papaccio, Federica, additional, Papaccio, Gianpaolo, additional, Park, Paul C., additional, Paterson, Alexander H.G., additional, Patiño-García, Ana, additional, Pienta, Kenneth J., additional, Popovic, Marko, additional, Rajarubendra, Nieroshan, additional, Redini, Françoise, additional, Reeves, Kimberley J., additional, Reisinger, Clemens, additional, Riminucci, Mara, additional, Rodriguez, Lidia, additional, Rogers, Michael J., additional, Ruggieri, Pietro, additional, Sacchetti, Benedetto, additional, Seibel, Markus J., additional, Selvarajah, Shamini, additional, Siegal, Gene P., additional, Sousa, Sofia, additional, Squire, Jeremy A., additional, Sternenberger, Andrea R., additional, Streitbuerger, Arne, additional, Stresing, Verena, additional, Sundaram, Murali, additional, Talbot, Julie, additional, Tang, Ping, additional, Tawadros, Thomas, additional, Terpos, Evangelos, additional, Thomas, Christian, additional, Thompson, Erik W., additional, Thompson, Michelle L., additional, Tirabosco, Roberto, additional, Tirino, Virginia, additional, Tirode, Franck, additional, Trichet, Valèrie, additional, van der Horst, Geertje, additional, van der Pluijm, Gabri, additional, Verrecchia, Franck, additional, Walkley, Carl R., additional, Wei, Shi, additional, and Zielenska, Maria, additional

Published
2015
Full Text
View/download PDF

17. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Author

Herrera, Fernanda G., primary, Ronet, Catherine, additional, Ochoa de Olza, Maria, additional, Barras, David, additional, Crespo, Isaac, additional, Andreatta, Massimo, additional, Corria-Osorio, Jesus, additional, Spill, Aodrenn, additional, Benedetti, Fabrizio, additional, Genolet, Raphael, additional, Orcurto, Angela, additional, Imbimbo, Martina, additional, Ghisoni, Eleonora, additional, Navarro Rodrigo, Blanca, additional, Berthold, Dominik R., additional, Sarivalasis, Apostolos, additional, Zaman, Khalil, additional, Duran, Rafael, additional, Dromain, Clarisse, additional, Prior, John, additional, Schaefer, Niklaus, additional, Bourhis, Jean, additional, Dimopoulou, Georgia, additional, Tsourti, Zoi, additional, Messemaker, Marius, additional, Smith, Thomas, additional, Warren, Sarah E., additional, Foukas, Periklis, additional, Rusakiewicz, Sylvie, additional, Pittet, Mikaël J., additional, Zimmermann, Stefan, additional, Sempoux, Christine, additional, Dafni, Urania, additional, Harari, Alexandre, additional, Kandalaft, Lana E., additional, Carmona, Santiago J., additional, Dangaj Laniti, Denarda, additional, Irving, Melita, additional, and Coukos, George, additional

Published
2021
Full Text
View/download PDF

19. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

Author

Fizazi, Karim, primary, Maldonado, Xavier, additional, Foulon, Stéphanie, additional, Roubaud, Guilhem, additional, McDermott, Raymond S., additional, Flechon, Aude, additional, TOMBAL, Bertrand F., additional, Supiot, Stephane, additional, Berthold, Dominik R., additional, Ronchin, Philippe, additional, Kacso, Gabriel, additional, Gravis, Gwenaelle, additional, Calabro, Fabio, additional, Berdah, Jean Francois, additional, Hasbini, Ali, additional, Silva, Marlon, additional, Thiery-Vuillemin, Antoine, additional, Rieger, Isabelle, additional, Tanguy, Marie Laure, additional, and Bossi, Alberto, additional

Published
2021
Full Text
View/download PDF

20. Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.

Author

Cathomas, Richard, primary, Rothschild, Sacha, additional, Hayoz, Stefanie, additional, Spahn, Martin, additional, Schardt, Julian, additional, Seiler, Roland, additional, Erdmann, Andreas, additional, Aeppli, Stefanie, additional, Mach, Nicolas, additional, Strebel, Raeto, additional, Hadaschik, Boris A., additional, Berthold, Dominik R., additional, Pless, Miklos, additional, Zihler, Deborah, additional, Schmid, Mathias, additional, Schneider, Martina, additional, Maniecka, Zuzanna, additional, and Petrausch, Ulf, additional

Published
2021
Full Text
View/download PDF

22. Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).

Author

Cathomas, Richard, primary, Petrausch, Ulf, additional, Hayoz, Stefanie, additional, Schneider, Martina, additional, Schardt, Julian Andreas, additional, Seiler, Roland, additional, Erdmann, Andreas, additional, Rothschild, Sacha, additional, Aeppli, Stefanie, additional, Mach, Nicolas, additional, Strebel, Raeto, additional, Hadaschik, Boris A., additional, Berthold, Dominik R., additional, Pless, Miklos, additional, Zihler, Deborah, additional, Schmid, Mathias, additional, Biaggi Rudolf, Christine, additional, and Spahn, Martin, additional

Published
2020
Full Text
View/download PDF

23. Treatment compliance and early toxicity in SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma.

Author

Papachristofilou, Alexandros, primary, Bedke, Jens, additional, Hayoz, Stefanie, additional, Fischer, Natalie, additional, Schiel, Xaver, additional, Schratzenstaller, Ulrich, additional, Krege, Susanne, additional, Lorch, Anja, additional, Aebersold, Daniel M., additional, Putora, Paul-Martin, additional, Berthold, Dominik R., additional, Zihler, Deborah, additional, Azinwi, Ngwa C., additional, Zengerling, Friedemann, additional, Dieing, Annette, additional, Mueller, Arndt-Christian, additional, and Cathomas, Richard, additional

Published
2020
Full Text
View/download PDF

26. Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study

Author

Necchi, Andrea Pond, Gregory Russell Plimack, Elizabeth R. and Niegisch, Guenter Yu, Evan Y. Pal, Sumanta K. Bamias, Aristotelis Agarwal, Neeraj Alva, Ajjai Shivaram Srinivas, Sandy Crabb, Simon J. Vaishampayan, Ulka N. Bowles, Daniel W. Berthold, Dominik R. Theodore, Christine Sridhar, Srikala S. Powles, Thomas Rosenberg, Jonathan E. Bellmunt, Joaquim and Galsky, Matt D.

Published
2018

27. Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.

Author

Necchi, Andrea, primary, Mariani, Luigi, additional, Lo Vullo, Salvatore, additional, Raggi, Daniele, additional, Giannatempo, Patrizia, additional, Bamias, Aristotelis, additional, Crabb, Simon J., additional, Bellmunt, Joaquim, additional, Yu, Evan Y., additional, Niegisch, Guenter, additional, Vaishampayan, Ulka N., additional, Theodore, Christine, additional, Berthold, Dominik R., additional, Srinivas, Sandy, additional, Sridhar, Srikala S., additional, Plimack, Elizabeth R., additional, Rosenberg, Jonathan E., additional, Powles, Thomas, additional, Galsky, Matthew, additional, and Sonpavde, Guru, additional

Published
2018
Full Text
View/download PDF

28. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy:Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Author

Necchi, Andrea, Sonpavde, Guru, Lo Vullo, Salvatore, Giardiello, Daniele, Bamias, Aristotelis, Crabb, Simon J, Harshman, Lauren C, Bellmunt, Joaquim, De Giorgi, Ugo, Sternberg, Cora N, Cerbone, Linda, Ladoire, Sylvain, Wong, Yu-Ning, Yu, Evan Y, Chowdhury, Simon, Niegisch, Gunter, Srinivas, Sandy, Vaishampayan, Ulka N, Pal, Sumanta K, Agarwal, Neeraj, Alva, Ajjai, Baniel, Jack, Golshayan, Ali-Reza, Morales-Barrera, Rafael, Bowles, Daniel W, Milowsky, Matthew I, Theodore, Christine, Berthold, Dominik R, Daugaard, Gedske, Sridhar, Srikala S, Powles, Thomas, Rosenberg, Jonathan E, Galsky, Matthew D, Mariani, Luigi, Necchi, Andrea, Sonpavde, Guru, Lo Vullo, Salvatore, Giardiello, Daniele, Bamias, Aristotelis, Crabb, Simon J, Harshman, Lauren C, Bellmunt, Joaquim, De Giorgi, Ugo, Sternberg, Cora N, Cerbone, Linda, Ladoire, Sylvain, Wong, Yu-Ning, Yu, Evan Y, Chowdhury, Simon, Niegisch, Gunter, Srinivas, Sandy, Vaishampayan, Ulka N, Pal, Sumanta K, Agarwal, Neeraj, Alva, Ajjai, Baniel, Jack, Golshayan, Ali-Reza, Morales-Barrera, Rafael, Bowles, Daniel W, Milowsky, Matthew I, Theodore, Christine, Berthold, Dominik R, Daugaard, Gedske, Sridhar, Srikala S, Powles, Thomas, Rosenberg, Jonathan E, Galsky, Matthew D, and Mariani, Luigi

Abstract

BACKGROUND: The available prognostic models for overall survival (OS) in patients with metastatic urothelial carcinoma (UC) have been derived from clinical trial populations of cisplatin-treated patients.OBJECTIVE: To develop a new model based on real-world patients.DESIGN, SETTING, AND PARTICIPANTS: Individual patient-level data from 29 centers were collected, including metastatic UC and first-line cisplatin- or carboplatin-based chemotherapy administered between January 2006 and January 2011.INTERVENTION: First-line, platinum-based, combination chemotherapy.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The population was randomly split into a development and a validation cohort. Generalized boosted regression modelling was used to screen out irrelevant variables and address multivariable analyses. Two nomograms were built to estimate OS probability, the first based on baseline factors and platinum agent, the second incorporating objective response (OR). The performance of the above nomograms and that of other available models was assessed. We plotted decision curves to evaluate the clinical usefulness of the two nomograms.RESULTS AND LIMITATIONS: A total of 1020 patients were analyzed (development: 687, validation: 333). In a platinum-stratified Cox model, significant variables for OS were performance status (p<0.001), white blood cell count (p=0.013), body mass index (p=0.003), ethnicity (p=0.012), lung, liver, or bone metastases (p<0.001), and prior perioperative chemotherapy (p=0.012). The c-index was 0.660. The distribution of the nomogram scores was associated with OR (p<0.001), and incorporating OR into the model further improved the c-index in the validation cohort (0.670).CONCLUSIONS: We developed and validated two nomograms for OS to be used before and after completion of first-line chemotherapy for metastatic UC.PATIENT SUMMARY: We proposed two models for estimating overall survival of patient

Published
2017

30. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Author

James, Nicholas D., primary, de Bono, Johann S., additional, Spears, Melissa R., additional, Clarke, Noel W., additional, Mason, Malcolm D., additional, Dearnaley, David P., additional, Ritchie, Alastair W.S., additional, Amos, Claire L., additional, Gilson, Clare, additional, Jones, Rob J., additional, Matheson, David, additional, Millman, Robin, additional, Attard, Gerhardt, additional, Chowdhury, Simon, additional, Cross, William R., additional, Gillessen, Silke, additional, Parker, Christopher C., additional, Russell, J. Martin, additional, Berthold, Dominik R., additional, Brawley, Chris, additional, Adab, Fawzi, additional, Aung, San, additional, Birtle, Alison J., additional, Bowen, Jo, additional, Brock, Susannah, additional, Chakraborti, Prabir, additional, Ferguson, Catherine, additional, Gale, Joanna, additional, Gray, Emma, additional, Hingorani, Mohan, additional, Hoskin, Peter J., additional, Lester, Jason F., additional, Malik, Zafar I., additional, McKinna, Fiona, additional, McPhail, Neil, additional, Money-Kyrle, Julian, additional, O’Sullivan, Joe, additional, Parikh, Omi, additional, Protheroe, Andrew, additional, Robinson, Angus, additional, Srihari, Narayanan N., additional, Thomas, Carys, additional, Wagstaff, John, additional, Wylie, James, additional, Zarkar, Anjali, additional, Parmar, Mahesh K.B., additional, and Sydes, Matthew R., additional

Published
2017
Full Text
View/download PDF

31. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Author

Necchi, Andrea, primary, Sonpavde, Guru, additional, Lo Vullo, Salvatore, additional, Giardiello, Daniele, additional, Bamias, Aristotelis, additional, Crabb, Simon J., additional, Harshman, Lauren C., additional, Bellmunt, Joaquim, additional, De Giorgi, Ugo, additional, Sternberg, Cora N., additional, Cerbone, Linda, additional, Ladoire, Sylvain, additional, Wong, Yu-Ning, additional, Yu, Evan Y., additional, Chowdhury, Simon, additional, Niegisch, Gunter, additional, Srinivas, Sandy, additional, Vaishampayan, Ulka N., additional, Pal, Sumanta K., additional, Agarwal, Neeraj, additional, Alva, Ajjai, additional, Baniel, Jack, additional, Golshayan, Ali-Reza, additional, Morales-Barrera, Rafael, additional, Bowles, Daniel W., additional, Milowsky, Matthew I., additional, Theodore, Christine, additional, Berthold, Dominik R., additional, Daugaard, Gedske, additional, Sridhar, Srikala S., additional, Powles, Thomas, additional, Rosenberg, Jonathan E., additional, Galsky, Matthew D., additional, and Mariani, Luigi, additional

Published
2017
Full Text
View/download PDF

33. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

Author

Bossi, Alberto, Foulon, Stéphanie, Maldonado, Xavier, Sargos, Paul, McDermott, Raymond S., Flechon, Aude, Tombal, Bertrand F., Supiot, Stephane, Berthold, Dominik R., Ronchin, Philippe, Kacso, Gabriel, Salem, Naji, Calabrò, Fabio, Berdah, Jean Francois, Hasbini, Ali, Silva, Marlon, Boustani, Jihane, Ribault, Hélène, and Fizazi, Karim

Published
2023
Full Text
View/download PDF

36. Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience

Author

Sturgeon, Jeremy F., primary, Moore, Malcolm J., additional, Kakiashvili, David M., additional, Duran, Ignacio, additional, Anson-Cartwright, Lynn C., additional, Berthold, Dominik R., additional, Warde, Padraig R., additional, Gospodarowicz, Mary K., additional, Alison, Ruth E., additional, Liu, Justin, additional, Ma, Clement, additional, Pond, Greg R., additional, and Jewett, Michael A., additional

Published
2011
Full Text
View/download PDF

45. Targeting Metastatic Prostate Cancer: The Search for Innovative Systemic Therapies.

Author

Berthold, Dominik R. and Moore, Malcolm J.

Abstract

The article focuses on the efficiency of prednisone or docetaxel and other innovative therapies in the treatment of prostate cancer to American men. The use of docetaxel in the treatment of people with prostate cancer was approved by the U.S. Food and Drug Administration in 2004 because its efficiency was proven during randomized clinical trials. However, the so-called drugs was improved due to the low survival advantage and the significant number of patients do not respond to chemotherapy.

Published
2006

46. Hormone-Resistant Prostate Cancer: New Therapies Needed.

Author

Berthold, Dominik R. and Tannock, Ian F.

Abstract

The article analyzes the management of hormone-refractory prostate cancer. There are several treatment options for this type of prostate cancer that include supportive care, secondary hormonal manipulations, chemotherapy and clinical trials. Moreover, the standard of care involves docetaxel, 75 mg every 3 weeks in combination with low-dose prednisone.

Published
2007

47. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Author

James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O'Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, and Sydes MR

Subjects
Abiraterone Acetate therapeutic use, Aged, Androgen Antagonists therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Follow-Up Studies, Hormones, Humans, Male, Prednisolone therapeutic use, Prednisone therapeutic use, Retrospective Studies, Treatment Outcome, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant drug therapy
Abstract

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50-0.71; P = 0.31 × 10 -9 ) favoured SOC + AAP, with 5-years survival improved from 41% SOC-alone to 60% SOC + AAP. This was similar in low-risk (HR = 0.55; 95% CI: 0.41-0.76) and high-risk (HR = 0.54; 95% CI: 0.43-0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group., (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Published
2022
Full Text
View/download PDF

48. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Author

Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Dangaj Laniti D, Irving M, and Coukos G

Subjects
Adaptive Immunity, Adenocarcinoma, Papillary immunology, Animals, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Disease Models, Animal, Female, Humans, Lymphocytes, Tumor-Infiltrating, Mice, Mice, Inbred C57BL, Ovarian Neoplasms immunology, Radiotherapy Dosage, Tumor Microenvironment, Adenocarcinoma, Papillary radiotherapy, Ovarian Neoplasms radiotherapy
Abstract

Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4 + and CD8 + T cells. LDRT elicited predominantly CD4 + cells with features of exhausted effector cytotoxic cells, with a subset expressing NKG2D and exhibiting proliferative capacity, as well as a unique subset of activated dendritic cells expressing the NKG2D ligand RAE1. We translated these findings to a phase I clinical trial administering LDRT, low-dose cyclophosphamide, and immune checkpoint blockade to patients with immune-desert tumors. In responsive patients, the combinatorial treatment triggered T-cell infiltration, predominantly of CD4 + cells with Th1 signatures. Our data support the rational combination of LDRT with immunotherapy for effectively treating low T cell-infiltrated tumors. SIGNIFICANCE: Low-dose radiation reprogrammed the tumor microenvironment of tumors with scarce immune infiltration and together with immunotherapy induced simultaneous mobilization of innate and adaptive immunity, predominantly CD4 + effector T cells, to achieve tumor control dependent on NKG2D. The combination induced important responses in patients with metastatic immune-cold tumors. This article is highlighted in the In This Issue feature, p. 1 ., (©2021 The Authors; Published by the American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

49. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Author

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, and Gillessen S

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cetuximab, Docetaxel, ErbB Receptors genetics, Humans, Male, Middle Aged, Neoplasm Metastasis, Orchiectomy, PTEN Phosphohydrolase genetics, Prostate-Specific Antigen blood, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Taxoids administration & dosage, Translational Research, Biomedical, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology
Abstract

Purpose: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer., Experimental Design: Patients with mCRPC progressing during or within 90 days after at least 12 weeks of docetaxel were included in this phase II trial. Treatment consisted of docetaxel (75 mg/m(2) every 3 weeks or 35 mg/m(2) on days 1, 8, 15 every 4 weeks) in combination with cetuximab (400 mg/m(2) on day 1 and then 250 mg/m(2) weekly). The primary endpoint was progression-free survival (PFS) at 12 weeks defined as the absence of prostate-specific antigen (PSA), radiographic, or clinical progression. Evaluation of known biomarkers of response and resistance to cetuximab (EGFR, PTEN, amphiregulin, epiregulin) was conducted., Results: Thirty-eight patients were enrolled at 15 Swiss centers. Median age was 68 years and median PSA was 212 ng/mL. PFS at 12 weeks was 34% [95% confidence interval (CI), 19%-52%], PFS at 24 weeks was 20%, and median overall survival (OS) was 13.3 months (95% CI, 7.3-15.4). Seven patients (20%) had a confirmed ≥ 50% and 11 patients (31%) a confirmed ≥ 30% PSA decline. About 47% of enrolled patients experienced grade 3 and 8% grade 4 toxicities. A significantly improved PFS was found in patients with overexpression of EGFR and persistent activity of PTEN., Conclusions: EGFR inhibition with cetuximab might improve the outcome of patients with mCRPC. A potential correlation between EGFR overexpression, persistent expression of PTEN, and EGFR inhibition should be investigated further., (©2012 AACR.)

Published
2012
Full Text
View/download PDF

50. [New drugs at the horizon for men with prostate cancer].

Author

Shabafrouz K, Bauer J, and Berthold DR

Subjects
Antineoplastic Agents pharmacology, Humans, Male, Antineoplastic Agents therapeutic use, Prostatic Neoplasms drug therapy
Abstract

Despite major progress in the understanding of biological mechanisms underlying metastatic prostate cancer, the treatment of men with advanced prostate cancer remains challenging. Several randomized controlled trials with promising or positive results are underway or just released. Here we discuss new treatments which might be used in clinic in the near future: hormonal treatments (Abiraterone and MDV3100), a new chemotherapy (Cabazitaxel), a cellular vaccine (Sipuleucel-T), anti-angiogenic drugs (Bevacizumab, Aflibercept), a new radioactive treatment (Alpharadin) and a new bone-protective agent (Deno-sumab).

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results